Insider Transactions in Q3 2025 at Rhythm Pharmaceuticals, Inc. (RYTM)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 09
2025
|
Pamela J. Cramer Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
15,572
-17.75%
|
$1,199,044
$77.41 P/Share
|
|
Jul 09
2025
|
Pamela J. Cramer Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,572
+19.4%
|
$264,724
$17.08 P/Share
|
|
Jul 09
2025
|
Christopher Paul German Corporate Controller & CAO |
SELL
Open market or private sale
|
Direct |
3,817
-54.12%
|
$305,360
$80.88 P/Share
|
|
Jul 09
2025
|
Christopher Paul German Corporate Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,850
+24.59%
|
$94,050
$33.6 P/Share
|
|
Jul 09
2025
|
Joseph Shulman Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,969
-28.04%
|
$613,613
$77.78 P/Share
|
|
Jul 09
2025
|
Joseph Shulman Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,969
+32.6%
|
$47,814
$6.8 P/Share
|
|
Jul 09
2025
|
Hunter C Smith Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
42,120
-9.52%
|
$3,285,360
$78.68 P/Share
|
|
Jul 09
2025
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,120
+20.94%
|
$252,720
$6.88 P/Share
|
|
Jul 07
2025
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,986
+5.64%
|
$41,916
$6.88 P/Share
|
|
Jul 02
2025
|
Alastair Garfield Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,319
-14.87%
|
$84,416
$64.7 P/Share
|
|
Jul 01
2025
|
Alastair Garfield Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,445
+50.0%
|
-
|